Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome

被引：21

作者：

Yassa, SK

Blessios, G

Marinides, G

Venuto, RC

机构：

[1] SUNY Buffalo, Sch Med, Dept Med, Div Nephrol, Buffalo, NY 14260 USA

[2] SUNY Buffalo, Sch Med, Dept Surg, Div Transplantat, Buffalo, NY 14260 USA

来源：

CLINICAL TRANSPLANTATION | 2005年 / 19卷 / 03期

关键词：

anti-CD20; hemolytic uremic syndrome; plasmapheresis; renal transplantation; Rituximab;

D O I：

10.1111/j.1399-0012.2005.00334.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Rituximab is a chimaeric monoclonal antibody directed against the CD20 antigen. It has been successfully used in B-cell malignancy and its efficacy in the treatment of in autoimmune hemolytic anemia and other autoimmune diseases is being investigated. There are also few case reports of its success in thrombotic thrombocytopenic purpura, but no reports of its use in hemolytic-uremic syndrome (HUS). We report a 36-year-old patient who had lost the function of her native kidneys secondary to HUS. After more than 1 year in clinical remission, she received a living unrelated kidney transplant. This immediately precipitated a severe relapse of HUS. The process was abrogated but not completely inactivated, despite over 40 plasma exchange treatments. Consequently, she was given Rituximab in courses of two to three doses, each dose 375 mg/m(2), at weekly intervals with remarkable stabilization of her disease for approximately 6 months.

引用

收藏

页码：423 / 426

页数：4

相关论文

共 16 条

[1] Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease [J].

Berentsen, S ;

Tjonnfjord, GE ;

Brudevold, R ;

Gjertsen, BT ;

Langholm, R ;

Lokkevik, E ;

Sorbo, JH ;

Ulvestad, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :79-83

[2] An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].

Boye, J ;

Elter, T ;

Engert, A .

ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535

[3] Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab [J].

Chemnitz, J ;

Draube, A ;

Scheid, C ;

Staib, P ;

Schulz, A ;

Diehl, V ;

Söhngen, D .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (02) :105-108

[4] Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [J].

Furlan, M ;

Robles, R ;

Galbusera, M ;

Remuzzi, G ;

Kyrle, PA ;

Brenner, B ;

Krause, M ;

Scharrer, I ;

Aumann, V ;

Mittler, U ;

Solenthaler, M ;

Lämmle, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1578-1584

[5] Rituximab therapy for refractory thrombotic thrombocytopenic purpura [J].

Gutterman, LA ;

Kloster, B ;

Tsai, HM .

BLOOD CELLS MOLECULES AND DISEASES, 2002, 28 (03) :385-391

[6] Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report [J].

Miller, RB ;

Burke, BA ;

Schmidt, WJ ;

Gillingham, KJ ;

Matas, AJ ;

Mauer, M ;

Kashtan, CE .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (07) :1425-1430

[7] Mechanisms of disease - Thrombotic microangiopathies [J].

Moake, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (08) :589-600

[8] Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus [J].

Perrotta, S ;

Locatelli, F ;

La Manna, A ;

Cennamo, L ;

De Stefano, P ;

Nobili, B .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) :465-467

[9] Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura [J].

Tsai, HM .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (04) :1072-1081

[10] Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome [J].

Tsai, HM ;

Chandler, WL ;

Sarode, R ;

Hoffman, R ;

Jelacic, S ;

Habeeb, RL ;

Watkins, SL ;

Wong, CS ;

Williams, GD ;

Tarr, PI .

PEDIATRIC RESEARCH, 2001, 49 (05) :653-659